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Background: As numerous experimental factors drive the acquisition, identification, and interpretation of protein-
protein interactions (PPIs), aggregated assemblies of human PPI data invariably contain experiment-dependent
noise. Ascertaining the reliability of PPIs collected from these diverse studies and scoring them to infer high-
confidence networks is a non-trivial task. Moreover, a large number of PPIs share the same number of reported
occurrences, making it impossible to distinguish the reliability of these PPIs and rank-order them. For example, for
the data analyzed here, we found that the majority (>83%) of currently available human PPIs have been reported
only once.
Results: In this work, we proposed an unsupervised statistical approach to score a set of diverse, experimentally
identified PPIs from nine primary databases to create subsets of high-confidence human PPI networks. We
evaluated this ranking method by comparing it with other methods and assessing their ability to retrieve protein
associations from a number of diverse and independent reference sets. These reference sets contain known
biological data that are either directly or indirectly linked to interactions between proteins. We quantified the
average effect of using ranked protein interaction data to retrieve this information and showed that, when
compared to randomly ranked interaction data sets, the proposed method created a larger enrichment (~134%)
than either ranking based on the hypergeometric test (~109%) or occurrence ranking (~46%).
Conclusions: From our evaluations, it was clear that ranked interactions were always of value because higher-
ranked PPIs had a higher likelihood of retrieving high-confidence experimental data. Reducing the noise inherent in
aggregated experimental PPIs via our ranking scheme further increased the accuracy and enrichment of PPIs
derived from a number of biologically relevant data sets. These results suggest that using our high-confidence
protein interactions at different levels of confidence will help clarify the topological and biological properties
associated with human protein networks.
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The development of high-throughput techniques during
the last decade has led to an unprecedented increase in the
volume of identified human protein-protein interactions
(PPIs). The currently available individual PPI data sets can
be roughly categorized into three sets: 1) proteome-wide,
large-scale screenings aimed at investigating all possible
PPIs [1-3], 2) semi-large-scale screenings aimed at investi-
gating the interactions between a specific group of proteins
(typically in a pathway) and all other proteins [4,5], and 3)* Correspondence: jaques.reifman@us.army.mil
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reproduction in any medium, provided the orsmall-scale, traditional studies aimed at detecting specific
PPIs among biologically interesting proteins, e.g., onco-
genes and their regulators. Although this latter set is still
numerically dominant (~80% of all PPIs belong to this set),
examples of the first two types of investigations are
expanding rapidly.
Given this extensive resource of known human PPIs and
their continuous accelerated growth, how to globally
analyze and aggregate the data remain a challenge. Statis-
tical methods for inferring confidence of protein interac-
tions can be broadly divided into two groups [6-8]: scoring
schemes that rely on the interaction data themselves (e.g.,
affinity purification/mass-spectrometry [AP/MS] data or
yeast two-hybrid [Y2H] data) and scoring schemes thatThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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interactions per se (e.g., functional annotation or gene ex-
pression data). Herein, we address the question of how to
extract high-confidence PPIs while relying only on the
aggregated interaction data themselves.
The most intuitive approach to infer high-confidence
PPIs is to score PPIs based on the number of times an
interaction has been reported [9-11]. However, using the
number of times a PPI has been reported (occurrence)
across different studies as the metric of reliability could
be influenced by numerous unknowable experimental
factors, e.g., recent studies have demonstrated that such
factors may result in decreased reliability of PPIs con-
taining frequently studied proteins [12]. Moreover, a
large number of PPIs share the same number of reported
occurrences, making it impossible to use occurrence
alone to establish the reliability of these PPIs and rank-
order them. For example, for the data analyzed here, we
found that the majority (>83%) of currently available
human PPIs have been reported only once.
Herein, we propose an unsupervised statistical approach
to score and rank a set of diverse, experimentally identified
PPIs. We applied this methodology to human PPIs (non-
physical associations excluded) aggregated from nine pub-
licly available primary databases that exclusively contain ex-
perimental data (Additional file 1): the Biomolecular
Interaction Network Database (BIND) [13], the Biological
General Repository for Interaction Datasets (BioGRID) [14],
the Database of Interacting Proteins (DIP) [15], the Human
Protein Reference Database (HPRD) [16], IntAct [17], the
Molecular INTeraction database (MINT) [18], the mam-
malian PPI database of the Munich Information Center on
Protein Sequences (MIPS) [19], PDZBase (a PPI database
for PDZ-domains) [20], and Reactome [21]. Our method
re-normalizes the importance of frequently occurring pro-
teins among PPIs to avoid giving added (and potentially
artificial) weight to those interactions. We estimated the im-
portance of a PPI by comparing the actual observed occur-
rence of a PPI with its occurrence in a randomized sample.
This calculation gauges the likelihood that the interaction
occurs by chance in the set of all observed PPIs. Using these
estimates, we rank-ordered the aggregated input PPI data
set, allowing us to create high-confidence subsets based on
a given rank threshold. At the lowest ranked threshold, all
interactions are included and there is no difference between
the ranked data and the original set of PPIs.
The presented scoring and ranking procedure can be
seen as an extension of our previous effort to infer high-
confidence interactions from the affinity purification raw
data, termed interaction detection based on shuffling
(IDBOS) [22], and, in the following, we will also refer to
our scoring and ranking scheme as IDBOS. Our proposed
procedure shares similarities to estimating probabilities of
observed interactions above a random background basedon the hypergeometric distribution [23], with the distinc-
tion that the IDBOS-generated probability density distribu-
tion functions correct for biases toward self-interaction
among frequently studied proteins. Although other meth-
ods exist for assigning confidence scores to PPIs, these gen-
erally require additional data or reference sets [24,25], or a
priori assumptions of network topology [26]. To the best of
our knowledge, this is the first application of an unsuper-
vised probabilistic scoring and ranking scheme to create
subsets of unbiased high-confidence human PPI networks.
We evaluated the improvement in using IDBOS-
ranked PPI data by comparing it with other methods and
assessing their ability to retrieve biological associations
from a number of diverse and independent reference
sets. These reference sets contain known biological data
that are either directly (e.g., crystallographically deter-
mined protein complexes) or indirectly (e.g., co-
expressed genes) linked to interactions between proteins.
The hypothesis we tested was that sets of highly ranked
PPIs are enriched in biological associations as deter-
mined from the diverse reference sets. We quantified the
average effect of using ranked protein interaction data to
retrieve this information and showed that, when com-
pared to randomly ranked interaction data sets, IDBOS
created a larger enrichment (~134%) than either ranking
based on the hypergeometric test (~109%) or occurrence
ranking (~46%).
From our evaluations, it was clear that ranked interac-
tions were always of value because higher-ranked PPIs
had a higher likelihood of retrieving biologically relevant
data. Statistically removing the biasing factors inherent
in aggregated PPI data via the IDBOS-ranking scheme
further increased the accuracy and enrichment of bio-
logical information associated with PPIs.
Results
Statistical scoring of human PPIs from literature data
We used the collection of human experimental and phys-
ical PPIs to create a set of 116,134 reported interactions,
containing 80,980 unique physical associations between
13,369 distinct proteins (see Materials and methods). Out
of the unique PPIs, 13,554 interactions were observed in
more than one experiment. The number of times a PPI has
been reported in the literature is an important metric for
inferring high-confidence interactions [9,10,27], but it
could also be dependent on other factors [12,28]. The
observed number of interactions of a protein is partly re-
flective of how often it has been studied (popularity). For
example, the top five connected proteins in the PPI data
are G-protein beta subunit (GNB1), G-protein gamma sub-
unit (GNGT1), G-protein alpha subunit (GNAL), ubiquitin
C (UBC), and tumor protein p53 (TP53), having 2,280,
2,248, 2,243, 1,899, and 1,097 reported interactions, re-
spectively. To normalize this popularity bias, we compared
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derived from the corresponding probability density distri-
bution functions generated from randomized data. In the
generation of the random interaction sets, we kept each
protein’s reported number of interactions fixed and, thus,
we expect the corresponding interaction probabilities of
proteins with a high (low) number of reported interactions
also to be high (low).
Note that the reported number of interactions involv-
ing a protein refers to the total number of observed PPIs
in the literature involving that specific protein. This is
different from a protein’s degree, which is defined as the
number of unique interacting protein partners. Thus,
while TP53 is associated with 1,097 observed PPIs, its
degree is reduced to 478 due to the multiple observa-
tions of many of the involved interactions.
Our calculations followed our previously described
procedures for generating Z-scores from sets of interact-
ing protein pairs [22]. Briefly, the aggregated PPI data
tabulates all pairs and the number of their occurrence in
the literature. From this list we counted, for each unique
pair between proteins i and j, how many times it oc-
curred Oij. Randomized versions of the original PPI list
were then created under the conditions that: 1) the pro-
tein identifiers and the number of times they occur are
preserved and 2) no interactions are allowed between
proteins of the same identifier, i.e., self-interactions are
not allowed. We generated M= 106 randomized PPI lists
and calculated the average number of times each PPI
from the original list occurred<Rij> and its standard
deviation σR. The corresponding Z-score was then calcu-
lated as,
Zij ¼ Oij − < Rij >σR ð1Þ
We further used the randomized data to estimate the
p-value pij of observing an interaction between proteins i
and j in the original data set. Briefly, for each unique pair
in the original PPI list, we calculated the number of
times it occurred in each of the n= 1, . . . ,M random rea-
lizations and created the normalized probability density
function PDFij, i.e., the probability of finding ORij ¼
0; 1; 2;::: occurrences by random chance. We estimated









Z-scores and p-values (Zij and pij) are legitimate
metrics for ranking an observed PPI, although they are
associated with different numerical properties and uncer-
tainties because of the limitations imposed on using a fi-
nite number of randomizations.Assessing p-values and Z-scores as PPI metrics
To assess the p-values and Z-scores as metrics in identi-
fying and ranking high-confidence protein interactions in
biological data sets, we compared the scored interactions
with an independent PPI data set that was not part of
the aggregated human data set. We used the human PPIs
derived from experimentally determined structural pro-
tein complexes deposited in the Protein Data Bank
(PDB) as outlined in the Materials and methods (Add-
itional file 2). To assess our scored data using this data
set as a benchmark, we selected only those interacting
protein pairs from the scored human PPI data where
both proteins appeared in the PDB-derived PPI data set.
We termed these pairs as “judgeable,” i.e., the proteins
appear in the benchmark data set, and we can judge
whether the interaction occurred or not. Thus, for a
given score, we determined how many of our judgeable
PPIs were interacting and non-interacting within
the benchmark set. Figure 1A-B shows the frequency of
interacting and non-interacting pairs as a function of Z-
scores and p-values. Interactions associated with high Z-
scores and small p-values were enriched with benchmark
interactions, indicating that both metrics were effective
in extracting high-confidence PPIs from the aggregated
literature data.
The procedure for shuffling the data allowed us to
compare the frequency of each observed interaction Oij
to that interaction’s probability density distribution func-
tion PDFij. This distribution is different for each inter-
action and depends on the number of distinct proteins
and interactions present in the entire network. Lacking
an analytical expression to generate the exact distribu-
tion functions, the procedure outlined in Equations 1
and 2 allowed us to generate estimates for both Z-scores
and p-values for each interacting pair. We found that
using either only p-values or only Z-scores to be inferior
to using the combined information (data not shown),
and, hence, we aggregated these two metrics by convert-
ing the value of each metric into a rank and generating
the average rank from both metrics for each interaction.
Interactions with the same p-value (or Z-score) were
assigned the same rank. If interactions had the same
rank in the final averaged-rank list, these interactions
were considered equivalent and analyzed together. The
ranked data are provided in the Supplementary materials
(Additional file 3). Instead of assigning post-priori prob-
abilities to already observed interactions, we only used
ranks and comparisons between ranked data to gauge
the biological information contained in these subsets.
Top-ranked IDBOS PPIs are different from the most
frequently reported PPIs
Table 1 shows the 20 top-ranked PPIs that were identi-








































Figure 1 IDBOS scoring schemes. The method presented is an extension to the interaction detection based on shuffling (IDBOS) method used
for mass spectrometry co-purification data [22]. We compared the set of known protein-protein interactions (PPIs) with randomized versions,
which preserve the number of interactions per protein, to obtain a Z-score and a p-value for each interaction. These quantities are schematically
outlined at the top, where a randomized probability density distribution function (PDF) is used to illustrate the p-value and Z-score calculations
for a particular interaction between proteins i and j. To evaluate these scoring schemes, we analyzed interactions derived from crystallographic
complexes in the PDB. Each human PPI was compared to a PPI derived from protein structure data in the PDB and assigned to one of two
subsets: interactions or non-interactions. If the PPI was present in the PDB interaction data set, the pair was assigned to the interactions set,
otherwise the pair was assigned to the non-interactions set. It is reasonable to assume that the first subset should be enriched with actual PPIs. (A)
Distribution of Z-scores corresponding to “interactions” and “non-interactions” assigned to PDB-derived PPIs, and (B) the corresponding p-value
distributions. We found that both p-values and Z-scores could distinguish these subsets, suggesting that they are useful metrics.
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(sorted by PPI occurrence). As expected, the most fre-
quently reported PPIs involved ubiquitously studied pro-
teins, such as those mentioned above (UBC and TP53)
as well as growth factor receptor bound 2 (GRB2), which
had 916 reported interactions. These interactions, how-
ever, were not observed in the top PPIs scored by the
IDBOS procedure. Instead, the top PPIs of the IDBOS
set were enriched with infrequently observed interac-
tions. Although we could not independently assess
whether these interactions are more “real” than the fre-
quently observed ones, they are partly supported by inde-
pendent literature citations. In fact, the proteins in these
interactions could be classified into two groups. The first
group comprised proteins that had the same specific func-
tion or were subunits of the same protein complex, such as
branched chain keto acid E1 alpha (BCKDHA) and
branched chain keto acid E1 beta (BCKDHB) [3,29], and
dynein cytoplasmic 2 intermediate chain 1 (D2LIC) and
dynein cytoplasmic 2 heavy chain 1 (DNCH2) [30,31]. The
second group comprised proteins that had a ligand/recep-
tor relationship, such as inducible T cell co-stimulator
(ICOS) and inducible T cell co-stimulator ligand (ICOSLG)
[32-34], or gastric inhibitory polypeptide (GIP) and gastric
inhibitory polypeptide receptor (GIPR) [35-38]. Among the
top 20 PPIs of the IDBOS set, two seemingly unrelated
protein pairs were actually closely related. The proteins in
the LTC4S/MGST1 interacting pair are actually two of the
six members of the membrane-associated proteins in the
eicosanoid and glutathione metabolism (MAPEG) family.Similarly, the top-ranked interaction between L-threonine
dehydrogenase (TDH) and aminoacetone synthetase (alias
of GCAT) catalyzes the conversion of L-threonine to gly-
cine [39].
Not only were the top-ranked sets different, but the
remaining bulk of the interactions also showed consider-
able changes in rank when the IDBOS p-values were
non-zero (See Additional files 3 and 4). To evaluate the
effect of this re-ranking of interactions, we then asked
whether these rankings have any impact in retrieving
biological information. We addressed this question by
comparing the ability of the two schemes to identify
known and inferred biological relationships based on
rank. The hypothesis we tested was that higher-ranked
subsets of the data sets are better at retrieving biological
information, and that IDBOS ranking provides a more
efficient way of retrieving this information than ranking
solely based on frequency of occurrence.
Evaluation of ranking schemes as measures of identifying
interacting proteins
To assess different PPI ranking schemes, we constructed
six benchmark reference sets derived from high-quality
experimental studies as detailed in Materials and meth-
ods. These independent data sets comprise PPIs detected
using 1) far-Western blotting, 2) isothermal titration cal-
orimetry, 3) nuclear magnetic resonance, 4) surface plas-
mon resonance, 5) direct interactions from protein
complex structures from the PDB, and 6) homologous
human PPIs derived from actual mouse PPI data. These
Table 1 Top 20 protein-protein interactions from IDBOS ranking
Protein i Protein j Protein-protein interaction i-j




GCAT 2 Glycine C-acetyltransferase TDH 2 L-threonine dehydrogenase 2 577.4 11.0 1328.0
CXCL16 4 Inducible T cell
co-stimulator
CXCR6 4 Inducible T cell
co-stimulator ligand
4 565.7 21.0 1333.0
CAPG
(NCAPG)
2 Non-SMC condensin I, G NCAPH 2 Non-SMC condensin I, H 2 534.5 22.0 1333.5
ICOS 5 Inducible T cell
co-stimulator
ICOSLG 5 Inducible T cell co-
stimulator ligand
5 507.7 23.0 1334.0
GPR103
(QRFPR)




3 474.3 28.0 1337.0
BCKDHA 5 Branched chain keto acid
dehydro. E1, alpha
BCKDHB 4 Branched chain keto acid
dehydro. E1, beta
4 471.4 29.0 1337.5
ARTN 2 Artemin (GDNF family) GFRA3 2 GDNF family receptor alpha
3
2 458.8 30.0 1338.0
CX3CL1 3 Chemokine (C-X3-C motif)
ligand 1
CX3CR1 3 Chemokine (C-X3-C motif)
receptor 1
3 442.3 57.0 1351.5
GIP 7 Gastric inhibitory
polypeptide
GIPR 9 Gastric inhibitory
polypeptide receptor
7 431.7 58.0 1352.0
POLG 4 Polymerase (DNA directed),
gamma
POLG2 3 Polymerase (DNA directed),
gamma2
3 428.6 59.0 1352.5
METTL1 5 tRNA(m7G46)-
methyltransferase
WDR4 2 tRNA (guanine-N(7)-
)-methyltran. subunit WDR4
2 417.0 60.0 1353.0
IL11 3 Interleukin 11 IL11RA 2 Interleukin 11 receptor,
alpha
2 408.2 61.0 1353.5
HBA2 68 Hemoglobin, alpha 2 HBB 76 Hemoglobin, beta 59 395.5 76.0 1361.0
CLEC2D 2 C-type lectin domain family
2, member D
KLRB1 3 Killer cell lectin-like receptor
subfamily B, 1
2 392.2 77.5 1361.8
LTC4S 2 Leukotriene C4 synthase MGST1 3 Microsomal glutathione S-
transferase 1
2 392.2 77.5 1361.8
CD97 4 Leukocyte antigen CD97 DAF 2 CD55 antigen 2 384.9 79.5 1362.8
D2LIC 2 Dynein, cyto-plasmic 2,
light intermed. chain 1
DNCH2 3 Dynein, cytoplasmic 2,
heavy chain 1
2 384.9 79.5 1362.8
IL22 6 Interleukin 22 IL22RA1 4 Interleukin 22 receptor,
alpha 1
4 383.1 81.0 1363.5
CD200 3 MRC OX-2 antigen CD200R1 2 CD200 receptor 1 2 378.0 82.0 1364.0
MLN 4 Motilin MLNR 7 Motilin receptor 4 369.8 98.0 1372.0
The top-20 ranked protein-protein interactions (PPIs) as identified by the interaction detection based on shuffling (IDBOS) method. We also provided the number
of times each individual protein was observed in the aggregated data set, the number of times the PPI was observed, and the corresponding Z-score and
associated fractional rank. All PPIs in this table have p-values <10−6, i.e., in the 106 randomization shuffles each of these PPIs were never observed to occur more
times than they were actually observed in the original data set. In the data set there were 5,288 PPIs with zero p-values and, hence, we assigned their uniform p-
value rank to be 2,644.5 (5288/2). This value was used together with each Z-rank to create the average rank in the last column. The estimated Z-score of a PPI
depends on the number of times each protein was observed in the original aggregated data set.
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retrieve known interactions derived from a variety of ex-
perimentally determined PPI data sets.
Using these six benchmark reference sets, we com-
pared the IDBOS-ranked data set with a set ranked by
PPI frequency of occurrence, a set ranked using the
hypergeometric test [23] (see Materials and methods,
Additional file 5), and two random data sets. The ran-
dom data sets included a set in which the PPIs them-
selves were retained, but their ranks were assignedrandomly, and a set where both the interactions them-
selves were randomized and were assigned a random
rank. In addition, we included the results obtained by
directly using the nine individual data sources that
formed the aggregated collection of human PPIs. The
objective here was to assess each ranking method’s cap-
ability to retrieve true interactions in each of the refer-
ence sets, as a function of rank, i.e., higher-ranked data
should contain a larger fraction of true interactions than
lower-ranked data.
Table 2 Top 20 protein-protein interactions from occurrence ranking
Protein i Protein j Protein-protein interaction i-j




MDM2 466 Mouse double
minute 2 homolog
TP53 1097 Tumor protein p53 130 86.0 3355 2999.8
TP53 1097 Tumor protein p53 UBC 1899 Ubiquitin C 64 18.4 30486 16565.3
HBA2 68 Hemoglobin, alpha 2 HBB 76 Hemoglobin, beta 59 395.5 76 1360.3
CBL 414 Cas-Br-M ecotro-
pic sequence
EGFR 626 Epidermal growth
factor receptor
46 42.6 11054 6849.3
CBL 414 Cas-Br-M ecotro-
pic sequence
GRB2 916 Growth factor
receptor bound 2
44 33.2 15615 9129.8
FANCA 217 Fanconi anemia,
complementation A
FANCG 143 Fanconi anemia,
complementation G
43 117.3 1808 2226.3
EGFR 626 Epidermal growth
factor receptor
UBC 1899 Ubiquitin C 41 15.8 34796 18720.3
BRCA2 199 Breast cancer 2,
early onset
RAD51 171 DNA repair
protein RAD51 homolog
1
40 104.4 2288 2466.3
HIF1A 207 Hypoxia inducible
factor 1, alpha
VHL 351 von Hippel-Lindau
tumor suppressor









STX1A 183 Syntaxin 1A 37 114.7 1920 2282.3
MAX 145 MYC associated factor X MYC 382 Proto-oncogene
c-Myc
36 73.4 4568 3606.3
BARD1 109 BRCA1 assoc. RING
domain 1
BRCA1 448 Breast cancer 1,
early onset
35 75.9 4279 3461.8
GRB2 916 Growth factor
receptor bound 2
SHC1 317 SHC transforming
protein 1
35 30.1 17593 10118.8
CDH1 167 Cadherin 1, type 1 CTNNB1 470 Catenin, beta 1 34 57.8 6876 4760.3
E2F1 168 E2F transcription
factor 1
RB1 385 Retinoblastoma 1 34 64.0 5853 4248.8
GRB2 916 Growth factor
receptor bound 2
SOS1 125 Son of sevenless
homolog 1
32 44.9 10232 6438.3
CCNA2 109 Cyclin A2 CDK2 286 Cyclin-dependent
kinase 2
31 84.3 3485 3064.8
EGF 76 Epidermal
growth factor
EGFR 626 Epidermal growth
factor receptor
31 68.2 5211 3927.8








30 53.1 7932 5288.3
Top 20-ranked protein-protein interactions (PPIs), as identified by the number of times they were observed in the aggregated data set. The quantities and
calculations are annotated as in Table 1, except that the data were sorted in decreasing order of PPI occurrence Oij. The proteins involved in these interactions are
easily recognizable, and this partly reflects an underlying study-bias of focusing research efforts on a smaller set of high-interest proteins.
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reference set, for each set we defined a protein pair from
the aggregated data set as a judgeable interaction if both
proteins appeared in the reference set; otherwise, we
assumed that the pair could not be judged by the refer-
ence set. If a judgeable interaction was observed in the
reference set, we termed it a true interaction. A good
scheme would rank true interactions before otherjudgeable interactions. To quantify the ability to retrieve
true interactions in each scored set, we extracted the
judgeable subset and, using each corresponding rank as a
threshold, we counted the numbers of judgeable and true
interactions with scores above the threshold. We defined
the number of true interactions as coverage and the frac-
tion of true interactions among those judgeable interac-
tions as accuracy.
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interaction benchmark reference sets. As expected, the
completely random PPI data set had no capability to re-
trieve direct protein interaction data. For the network
created by assigning random ranks to existing PPIs, the
accuracy was almost uniform at any given coverage.
IDBOS, hypergeometric, and frequency of occurrence
ranking were each associated with enhanced accuracy at
higher ranks, thus indicating that true interactions
ranked before other judgeable interactions. We assessed
the overall performance of the ranking methods by cal-
culating relative improvement compared to using no
ranking, which is equivalent to assigning random ranks
to the existing data. For the accuracy as a function of
coverage plots shown in Figure 2, we calculated the aver-
age accuracy < A >over all ranks r as,




accuracy rð Þ  n rð Þ ð3Þ
where n(r) is the number of true PPIs at rank r and N is
the sum of all n(r)’s. The gain of using IDBOS, hypergeo-


















































Figure 2 Retrieving protein-protein interactions. The proposed interact
compared with hypergeometric test ranking, frequency of occurrence ranki
interactions [PPIs] take random ranks), a randomly rewired interaction set, a
using benchmark reference sets derived from six independent experimenta
calorimetry, (C) nuclear magnetic resonance, (D) surface plasmon resonanc
complex structures collected from PDB (contacts determined using the join
interactions. We assumed that each reference set could only judge a PPI w
(judgeable). We assessed performance by coverage (number of true interact
interactions) as a function of varying ranking thresholds (when applicable).
scored by occurrence alone, multiple PPIs possessed the same score, and t
PPIs with an observed occurrence ≥2.by comparing the average accuracy < A > to the ran-
domly ranked data < AR >as,




Table 3 lists the gains in average accuracies in each
reference set for the different ranking schemes. The
IDBOS ranking scheme shows the greatest increase com-
pared to using randomly assigned ranks, achieves a two-
fold increase in accuracy compared with using frequency
of occurrence ranking, and consistently outperforms the
hypergeometric ranking. In practice, one should also
note that selecting any high-accuracy subset of PPIs
based on ranked interaction data creates a smaller data
set and lowers the overall PPI coverage.
The independent scores (Z-scores or p-values) were
typically better than, or equivalent to, the hypergeo-
metric method: Z-score ranking was close to the IDBOS,
and better than the hypergeometric, whereas the p-value
ranking was not as good as the hypergeometric. For ex-
ample, using the PDB benchmarking set, the gains of the





























ion detection based on shuffling (IDBOS) ranking scheme was
ng, one randomly ranked set (where the observed protein-protein
nd nine individual data sets. We compared these ranking schemes
l data sets, namely: (A) far-Western blotting, (B) isothermal titration
e, (E) protein pairs in direct contact with each other within protein
tly buried surface area), and (F) mouse homologous protein
hen each of its two proteins actually appeared in this reference set
ions) and accuracy (fraction of true interactions among judgeable
The higher-ranked thresholds are to the left in the plots. In the set
he second right-most symbol entry corresponds to the collection of
Table 3 Evaluation of different ranking schemes
Reference set IDBOS Hypergeometric Occurrence Random rank
<A> Gain <A> Gain <A> Gain <A>
Far-Western blotting 0.409 184% 0.313 118% 0.178 24% 0.144
Isothermal titration calorimetry 0.542 215% 0.469 173% 0.286 66% 0.172
Nuclear magnetic resonance 0.632 157% 0.534 117% 0.331 34% 0.246
Surface plasmon resonance 0.567 160% 0.496 128% 0.320 47% 0.218
PDB complex PPIs 0.842 258% 0.746 217% 0.566 141% 0.235
Mouse homologous PPIs 0.318 222% 0.293 198% 0.207 110% 0.099
The average accuracy<A> and gain associated with interaction detection based on shuffling (IDBOS), hypergeometric test ranking, and occurrence-ranking schemes
were estimated using Equations 3 and 4. The value associated with the randomly ranked data set does not represent a random protein-protein interaction (PPI) data set
as only the rank, and not the interactions themselves, were randomized. The tested reference sets contain PPIs derived from 1) far-Western blotting, 2) isothermal titration
calorimetry, 3) nuclear magnetic resonance, 4) surface plasmon resonance experiments, 5) known protein crystal complexes contained in the Protein Data Bank (PDB), and
6) those derived from experimentally determined mouse PPIs. We tested whether the numerical differences in values of<A> for each pairwise comparison within each
reference set were due to chance using the t-test, and rejected this hypothesis with a p-value of <10-6.
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data were 258%, 253%, 217%, and 216%, respectively;
using the mouse homologous benchmarking set, the
gains were 222%, 211%, 198%, and 155%, respectively.
Thus, the IDBOS combined rankings consistently out-
performed all attempted scoring schemes.
IDBOS versus hypergeometric test rankings
The observed differences in Table 3 and Figure 2 between
the IDBOS and hypergeometric test rankings warrants fur-
ther comment. The fundamental difference between the
IDBOS and hypergeometric test rankings lies in how they
account for interactions between self-interacting proteins.
For the IDBOS randomized data, each pair of proteins was
re-assigned an interaction partner such that no self-inter-
acting protein pairs remained in the final set used to con-
struct the probability density distribution functions. In the
hypergeometric test, self-interacting protein pairs were
assigned finite probabilities of occurrence based on a back-
ground distribution for each protein pair, which was differ-
ent from IDBOS. Conceptually, the sum of the probability
of observing all interactions with a given protein A among
all other proteins pAA, pAB, pAC, etc., was the same in both
schemes. However, the constraint that pAA was zero in
IDBOS and pAA was non-zero in the hypergeometric test,
re-distributed the probabilities such that any interaction
probability pAB between protein A and another protein B
could be different in the two schemes. This strongly influ-
enced the probability of detecting proteins that occurred
with high frequency in the data set.
The effect of including or excluding self-interacting pro-
tein pairs was magnified in the evaluation of interactions
involving popular proteins. In the hypergeometric test, the
likelihood of randomly generating self-interacting protein
pairs is roughly proportional to the square of the number
of times the protein appears in the data set. In practice, this
leads to an underestimate of the occurrence of non-iden-
tity pairs in the random data, and this increases thesignificance attached to the observed non-identity PPIs in-
volving popular proteins. The effect on ranking PPIs was
considerable, e.g., among the top 20 occurrence-ranked
interactions listed in Table 2, 11 appeared in the top 20
hypergeometric test ranking scheme. In fact, the first oc-
currence-ranked interaction between MDM2 and TP53
was still the second ranked interaction based on the hyper-
geometric test. Figure 3 shows the overlap of interactions
among top-ranked PPIs based on IDBOS, the hypergeo-
metric test, and frequency of occurrence rankings. As ex-
emplified above, there was a noteworthy overlap (>0.40)
between the ranking results in the frequency of occurrence
and the hypergeometric test rankings for all ranks tested.
In contrast, the first 103 top-ranked IDBOS PPIs showed
low overlap (~0.10) with the frequency of occurrence
ranked PPIs, but higher similarity (~0.36) to the ranked
PPIs identified using the hypergeometric test. Thus, the
high overlap between occurrence and hypergeometric
rankings suggested that the inadvertent biases introduced
by frequent investigations of popular proteins could not be
completely disentangled by the hypergeometric-ranking
scheme. Furthermore, we verified that consensus ranking
schemes that included the average rank of all three ranking
methods, or combining IDBOS and hypergeometric test
rankings only, did not increase the accuracy beyond using
IDBOS rankings (data not shown). Instead, we contend
that the corresponding probability density distribution
functions generated by IDBOS are the most appropriate to
gauge unbiased PPIs in this data set.
Enrichment of known domain-domain interactions
The hypothesis that PPIs are mediated by a smaller set
of specific domain-domain interactions (DDIs) that are
repeatedly used, can be exploited by inferring DDIs from
known PPIs and then predicting novel PPIs from the in-
ferred DDI set [40,41]. A high-confidence PPI set, such
as the collection of highly ranked PPIs, is more likely to






















Figure 4 Recovery of known domain interactions from protein
interactions. The proposed interaction detection based on shuffling
(IDBOS) ranking scheme was compared with the frequency of
occurrence ranking, one randomly ranked set (where the observed
protein-protein interactions (PPIs) take random ranks), and a
randomly rewired interaction set in identifying known domain-
domain interactions (DDIs). We assessed performance by calculating
the fraction of true DDIs among the judgeable interactions as a
function of varying ranking thresholds. In the set scored by
occurrence alone, multiple PPIs possessed the same score, and the
second right-most symbol corresponds to the collection of PPIs with
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Figure 3 Overlap of top-ranked protein interactions. The overlap
of top-ranked protein-protein interactions (PPIs), based on a pairwise
comparison of three interaction evaluation schemes: interaction
detection based on shuffling (IDBOS), hypergeometric test ranking,
and frequency of occurrence ranking. The overlap between
hypergeometric and occurrence rankings was considerable. The
right-most point in the graph corresponds to the case where all
interactions are included and, by definition, the three schemes
overlap. For intermediate rankings, IDBOS shows considerably lower
overlap with either method, indicative of distinct and different sets
of top-ranked PPIs. The right-most curve (Random) shows the
expected overlap fraction of top-ranking PPIs from two completely
random rankings, emphasizing that even though the overlap fraction
between IDBOS and Occurrence ranking was low, it was
considerably higher than what would be expected by chance alone.
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pairs as a function of the rank threshold. As before, we
only considered judgeable protein pairs whose domains
appear in the set of known DDIs. The known DDI set
was inferred from the PDB crystal structures [42]. As two
random controls, we also randomly ranked and randomly
rewired the judgeable protein pairs. Figure 4 shows that
more stringent ranking thresholds (represented by fewer
“Top judgeable PPIs” in Figure 4) resulted in higher enrich-
ments of DDIs among all domain pairs between interacting
proteins for both the IDBOS and frequency of occurrence
rankings. This behavior was in contrast with the two ran-
dom controls, which did not show such enrichments.
Table 4 quantifies the improvement gained by ranking the
data relative to no rankings. Within the same top number
of PPIs, the IDBOS set had a higher enrichment of known
DDIs than sets ranked either by the hypergeometric test or
by frequency of occurrence, indicating a potential applica-
tion of the IDBOS-ranked PPI sets for the inference of ac-
curate DDIs.
Evaluation of ranking PPIs as a means of retrieving
biological information
Up until now, the different scoring schemes were used
to evaluate reference data sets that can be considered tobe directly related to interacting proteins. We next evalu-
ated the improvement that could be gained by using the
differently ranked data sets to rank-order the interactions
in reference data sets that are presumed to be enriched
with interacting proteins, i.e., in sets of proteins that
share the same Kyoto Encyclopedia of Genes and Gen-
omes (KEGG) pathway, are implicated in the same dis-
ease, share Gene Ontology (GO) function, or tissue
mRNA expression levels.
Case I: Enrichment of KEGG co-pathway gene pairs
Genes encoding interacting proteins are more likely to be
part of the same pathway. Hence, the fraction of PPIs that
are annotated to belong to the same pathway should be lar-
ger in sets containing higher-ranked PPIs. We used KEGG
pathway data [43] to define co-pathway gene pairs, as out-
lined in the Materials and methods. For each investigated
PPI set, we excluded protein pairs involving proteins that
did not participate in any KEGG pathway (these were
deemed to be non-judgeable). Figure 5A shows the results
of this analysis. We confirmed the correlation between co-
pathway membership of a protein pair and its rank thresh-
old in both the IDBOS and the frequency of occurrence
ranking schemes, as well as the absence of correlation in
the two random controls. Overall, IDBOS ranking outper-
formed frequency of occurrence ranking by a factor of four
for enrichment of co-pathway gene pairs among selected
Table 4 Domain-domain interaction enrichment
Reference set IDBOS Hypergeometric Occurrence Random rank
Fraction Gain Fraction Gain Fraction Gain Fraction
DDI 0.225 48% 0.215 42% 0.174 15% 0.152
The fraction of true domain-domain interactions (DDIs) retrieved with interaction detection based on shuffling (IDBOS), hypergeometric test ranking, occurrence
ranking, and randomly ranked data. We calculated the reported fraction and gain associated with the different ranking schemes as outlined in Equations 3 and 4.
We tested whether the numerical differences in the fraction values for each pairwise comparison were due to chance using the t-test, and rejected this hypothesis
with a p-value of <10-24.
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metric ranking was substantially smaller than that of
IDBOS ranking. There is a discontinuity in the curve for
the frequency of occurrence ranking scheme, which was
caused by hundreds of interactions between three subunits
of G protein (GNAL, GNB1, and GNGT1) and olfactory
proteins which were supported by seven publications
(Additional file 1). We reviewed these publications and
found that this literature support was weak, with some
based solely on gene expression evidence of those olfactory
genes [44]. Among these hundreds of PPIs, those involved


































Figure 5 Recovery of biological co-annotations from protein interactions
ranking scheme was compared with the frequency of occurrence ranking,
interactions (PPIs) take random ranks), and a randomly rewired interaction s
reference sets were: (A) co-pathway gene pairs, (B) co-disease susceptibility
co-expressed gene pairs. We assessed performance by calculating the enric
function of varying ranking thresholds. In the set scored by occurrence alon
symbol corresponds to the collection of PPIs with an observed occurrencewere not supported by KEGG pathway data, resulting in a
sharp drop in accuracy.
Case II: Enrichment of co-disease gene pairs
Genomic variations may underlie different susceptibil-
ities to disease, e.g., individuals with specific single nu-
cleotide polymorphisms (SNPs) can develop, or be pre-
disposed to, a particular disease phenotype. Furthermore,
genes encoding interacting proteins are more likely to
occur within the same disease classification [45]. Using
the gene co-disease data extracted by Goh et al. [45]

























. The proposed interaction detection based on shuffling (IDBOS)
one randomly ranked set (where the observed protein-protein
et in retrieving biological relationships from diverse reference sets. The
gene pairs, (C) functionally related gene pairs, and (D) tissue
hment fraction of true PPIs among the judgeable interactions as a
e, multiple PPIs possessed the same score, and the second right-most
≥2.
Table 5 Evaluation of ranked interactions to detect biological relationships
Reference set IDBOS Hypergeometric Occurrence Random rank
Fraction Gain Fraction Gain Fraction Gain Fraction
Co-pathway 0.350 76% 0.315 59% 0.235 18% 0.199
Co-disease 0.306 91% 0.298 86% 0.214 34% 0.160
Co-function 0.122 48% 0.123 50% 0.095 16% 0.082
Co-expression 0.036 15% 0.035 14% 0.033 6% 0.031
The fraction of biological associations retrieved using interaction detection based on shuffling (IDBOS), hypergeometric test ranking, occurrence ranking schemes, and
randomly ranked data. We calculated the reported fraction and gain associated with the different ranking schemes as outlined in Equations 3 and 4. The four reference
sets tested contain putative biological relationships pertaining to protein interactions that are in the same Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
(co-pathway), implicated in the same disease (co-disease), share Gene Ontology (GO) function (co-function), or tissue expression levels (co-expression). We tested
whether the numerical differences in the fraction values for each pairwise comparison within each references set were due to chance using the t-test, and rejected this
hypothesis with a p-value of <10-2.
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ease gene pairs as a function of rank threshold (Figure 5B,
Table 5). A gene pair was termed a co-disease gene pair if
their SNPs led to susceptibility to the same disease. With
this co-disease gene pair set, we also extracted judgeable
protein pairs whose encoding genes appeared in this co-
disease set (i.e., genes that have an actual disease annota-
tion). Similar to the previous analyses, the IDBOS-scored
set showed an enhanced probability of identifying existing
disease-susceptible genes as compared with the frequency
of occurrence ranking scheme, hypergeometric-based
rankings, or random controls.
Case III: Enrichment of GO co-function gene pairs
Figure 5C shows the ability of the IDBOS and frequency
of occurrence ranking schemes to identify PPIs whose
proteins share the same gene ontology (GO) function.
Both ranking schemes displayed a similar rank-
dependent enrichment of co-function proteins compared
to the randomly ranked (all ranks have the same import-
ance) and randomly rewired (interactions are random)
data set. Table 5 indicates that the improvements of the
ranking schemes compared to randomly ranked data are
relatively modest in retrieving functionally related gene
pairs. As pointed out by Gillis and Pavlidis [28], the abil-
ity of PPI networks to distinguish co-functionality is
largely influenced by the multifunctional nature of the
gene annotations schemes themselves. In this case, the
IDBOS, hypergeometric, and occurrence ranking
schemes themselves will also have less influence on the
retrieval of functionally related protein pairs compared
to the annotation scheme itself.
Case IV: Enrichment of tissue co-expression gene pairs
Finally, we examined the occurrence of interacting protein
pairs in a large data set that maps out the global mRNA
expression levels for ~20,000 human genes in 32 normal
tissues [47]. For detail on the construction of this reference
set, see Materials and methods. The biological hypothesis
tested here examined co-expression of two mRNAs in the
same tissue as indicative that the corresponding proteinshad higher probability of interaction. Figure 5D shows the
fraction of PPIs retrieved as a function of ranking scheme.
Overall, the fraction of PPIs contained in the co-expression
data set was lower than that of the other biological refer-
ence sets examined above. However, the investigated rank-
ing schemes were able to produce ranked data sets that
contain a slightly larger fraction of co-expressed PPIs than
using no ranking (Table 5).
Topological differences of ranked PPI networks
Data sets of protein interactions are commonly repre-
sented as graphs or networks of protein interactions, and
applying network topology metrics to characterize the bio-
logical role of PPIs has attracted wide attention
[9,10,22,48]. The presence of confounding factors, e.g., pro-
tein abundance [49] or popularity [12], can strongly influ-
ence the topological properties of the network. Here, we
used subsets of highly ranked PPIs derived from using ei-
ther IDBOS or occurrence ranking to select smaller high-
confidence networks. Figure 6A shows the overall net-
works constructed from the top-ranking PPIs correspond-
ing to 4,425, 6,561, and 13,554 interactions selected based
on the number of PPIs that have more than or equal to
four, three, and two reported occurrences, respectively. Fig-
ure 6B shows the corresponding degree distribution, i.e.,
the distribution of the number of unique interacting part-
ners each protein has (Degree), as well as the overall de-
gree distribution for the entire network (All).
Selecting highly ranked subsets of PPIs, using either
IDBOS or occurrence, had the effect of reducing the
number of high-degree proteins (hubs) in the overall net-
work. This effect was most pronounced in the top-
ranked IDBOS networks, which effectively down-weights
interactions of popular proteins. The resulting top-
ranked IDBOS networks were not dominated by hub
interactions, but show a more distributed interaction
network, with distinct topological and scaling properties.
Discussion
Single experiments designed for large-scale detection of
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Figure 6 Network topology of ranked interactions. (A) We reconstructed the corresponding top-ranked protein-protein interactions (PPIs)
networks using both interaction detection based on shuffling (IDBOS) ranking and frequency of occurrence ranking. The columns of 4,425, 6,561,
and 13,554 top-ranked interactions corresponds to selecting PPIs with≥ 4, ≥ 3, and≥ 2 reported occurrences, respectively. These interactions were
distributed among roughly twice as many proteins using IDBOS ranking than in occurrence ranking. (B) The degree distribution for each selected
PPI network was analyzed and compared to the distribution of all aggregated interactions (All). The higher-ranked PPI data sets were associated
with fewer proteins that had a large number of interacting partners (hubs). As visualized in (A), the top-ranked networks were instead
characterized by more evenly distributed interactions in a loosely interconnected network.
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observations, across many different experiments, of a
particular PPI also lend confidence that this interaction
occurs in nature. One would then conclude that if one
aggregated all known PPI experiments, the more times a
particular PPI occurred, the more confident one would be
of the interaction. We found a somewhat counterintuitive
result in that ranking PPIs in order of the number of times
a PPI has been observed was actually not the optimal way
of assessing the importance of frequently reported interac-
tions. Instead, we used the IDBOS method, which ranksinteracting protein pairs in the observed PPI data sets as
compared to random occurrences derived from an empir-
ically reconstructed probability density distribution func-
tion specific to each interaction. We then used these ranks
to order the PPI data and showed that this approach con-
sistently identified more known protein associations in nu-
merous benchmark reference sets than using either
hypergeometric test rankings or simply frequency of occur-
rence. The improvement of IDBOS over the hypergeo-
metric test results stems from the differences in the
underlying random distributions in the two schemes.
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tions on self-interacting proteins, by construction, the
IDBOS procedure sets their probability of occurrence to
zero even for the random case. The input data contain no
self-interacting proteins; therefore, the corresponding ran-
dom probability density distribution functions generated
by IDBOS seem to be the most appropriate to gauge un-
biased PPIs in this data set.
We evaluated the improvement in using ranked PPI data
to identify known protein relationships in eleven independ-
ent reference sets, including direct and indirect readouts of
protein interactions. We used a large number of different
reference sets to perform as comprehensive an analysis as
possible, as each reference set only covers a specific subset
of protein interactions. It was clear that ranking interactions
was of value, because higher-ranked PPIs had better success
at retrieving protein associations. Across all sets investi-
gated, occurrence ranking improved the performance by
46% compared to using non-ranked data, hypergeometric
ranking achieved a 109% increase, and the IDBOS ranking
scheme achieved a 134% increase. This conformed to the
assumption that aggregating and creating high-confidence
subsets of data creates added value, albeit at a cost of redu-
cing the overall number of PPIs that can be considered.
Conclusions
We have developed a statistical approach to infer subsets of
high-confidence human PPIs, and showed that ranked data
can consistently enrich the accuracy of the retrieved PPI data
in these sets. Our IDBOS method was more successful in
ranking interactions than using either the number of times
an interaction has been observed across experiments or
rankings based on the hypergeometric test. Furthermore,
using either IDBOS or hypergeometric scoring schemes gen-
erates unique ranks for almost all interactions, as opposed to
the frequency of occurrence method, in which many interac-
tions have the same integer score corresponding to the num-
ber of observed occurrences. The IDBOS ranking increased
accuracy and enrichment of protein interaction data asso-
ciated with PPIs by more than two-fold compared to simply
ranking interactions based on observed occurrences. We
achieved this improvement by comparing the observed inter-
action data with a probability density distribution function
that does not inflate the statistical importance of interactions
associated with frequently studied proteins. These results
suggest that using our high-confidence protein interactions
at different levels of confidence could help clarify the de-
pendence on confidence on topological and biological prop-
erties associated with human protein networks.Materials and methods
Statistical scoring of PPIs from aggregated experimental data
We downloaded the collection of PPIs in October 2011
from the nine databases that covers the bulk of allknown experimentally determined PPIs. Databases of
non-primary nature, i.e., containing aggregated data and/
or predicted and inferred interactions, were excluded.
From this collection, we extracted the subset of human
physical PPIs, consisting of PPIs from both large-, semi-
large-, and small-scale experimental studies. Because Reac-
tome has no standardized annotations describing physical
associations or direct interactions, instead we extracted
PPIs annotated as “direct complexes.” We treated each
interaction reported by each study (identified by a unique
publication ID) as a unique record by deleting redundant
copies arising from the overlaps among the nine databases.
In total, we analyzed 13,369 proteins, 80,980 PPIs, and
116,134 records (Additional file 1). The computational
procedure to generate 106 random realizations of the PPI
data set and compute the corresponding p-values and Z-
scores took ~2,000 minutes on a dual core Xeon Irwindale
3.6 GHz 64-bit Linux server equipped with 4 GB of RAM.
We used fractional rankings, i.e., PPIs that had the same
score received the same ranking number, which is the
mean of what they would have received under ordinal
rankings. The Supplementary material provides the scored
and ranked PPI data set, with equivalently ranked interac-
tions tabulated in arbitrary order.
To rank interactions based on an alternative statistical
method compared to IDBOS and frequency of occur-
rence, we included ranks based on a hypergeometric test
[23]. For two proteins, i and j, given that the interaction
between i and j occurred Nij times, the probability (pij)
for these two proteins to have this or a larger number of
interactions by chance was approximated using a hyper-















where Ni (Nj) is the number of times protein i (j) was
observed in the aggregated data set, and N is the total
number of interactions in the aggregated data set of PPIs.
This formulation is correct in the limit of N >>Ni, Nj,
which was satisfied in this data set. Finally, we ranked the
PPI data based on the calculated probabilities.
PDB interactions
We mapped all PDB sequences (downloaded in October
2010) to the human protein sequences stored in the Uni-
ProtKB/Swiss-Prot database (downloaded in June 2008)
and obtained 649 protein complexes that contained at
least two different human proteins. We then calculated
the contact area of each intra-complex human protein
pair using the program EMPIRE [50], to determine
which protein pairs interact. For protein pairs occurring
in multiple complexes, we selected the pair with the lar-
gest contact area as an interacting pair. We collected 281
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contact areas ranging from 0.1 to 183 nm2, as a reference
set for known human PPIs derived from structural data
(Additional file 2).
Reference sets from the HIPPIE database
We extracted four reference sets from the Human Inte-
grated Protein-Protein Interaction rEferenc (HIPPIE) data
set (http://cbdm.mdc-berlin.de/tools/hippie/ information.
php, January 2012), each of which consists of PPIs detected
by a top-scored experiment technique (score = 10, specified
with European Bioinformatics Institute (EBI) term ID, and
number of PPIs >100). The extracted data set contained
PPIs derived from 1) far-Western blotting, 2) isothermal ti-
tration calorimetry, 3) nuclear magnetic resonance, and 4)
surface plasmon resonance experiments.
Homologous human PPIs from mouse data
We extracted the subset of mouse physical PPIs from the
above collection and constructed a homologous human
PPI set according to the sequence homology between
mouse and human proteins defined by the National Center
for Biotechnology Information (NCBI) homology mapping
scheme (ftp://ftp.ncbi.nih.gov/pub/HomoloGene/, October
2009). We used this homologous human PPI set (contain-
ing 3,148 interactions between 5,632 proteins) as a refer-
ence data set reflective of direct protein interactions.
Domain annotation and interaction data
We used the Pfam-A families of the Pfam21.0 database
as the source for domain annotation [51]. We also down-
loaded the DDI set inferred from PDB crystal structures
from the iPfam database [42]. This DDI set contains
4,030 interactions between 2,837 Pfam-A domains.
Co-disease susceptibility gene pairs
We used the disease susceptibility gene data of Goh
et al. [45], which was constructed by processing OMIM
raw data [46]. There were 43,249 pairs between 3,670
genes whose two genes were susceptible to at least one
common disease. We used these pairs to represent the
co-disease susceptibility gene pairs.
Co-function gene pairs
We downloaded the GO annotation data (www.geneon-
tology.org, June 2010) to identify a set of functionally
related gene pairs as a reference set. For each gene, we
expanded its GO annotation list by including all ances-
tors of each member in the list. For two genes, g and h,
given that they had ngh GO annotations in common, the
probability (pgh) for these two genes to have this or lar-
ger annotation overlap by chance was estimated from
the hypergeometric distribution as follows:pgh ¼ ∑













where Ng (Nh) is the number of GO annotations of gene
g (h) and T is the total number of unique GO annota-
tions. We used –log(pgh) as the score and chose the top
1% of all gene pairs as a reference set, resulting in
1,502,420 co-function pairs for this reference set.
Co-pathway gene pairs
The KEGG pathway data file (hsa_gene_map.tab) was
downloaded from its Web site (ftp://ftp.genome.jp/pub/
kegg/pathway/, June 2010), which lists the pathways that
each annotated gene participates in. Similar to the co-
function score described above, the co-pathway score
was also computed using the hypergeometric distribution
method. We chose the top 1% as the reference set of sig-
nificant co-pathway gene pairs (139,841 pairs).
Tissue co-expression of gene pairs
We used a global expression data set containing mRNA
expression levels for ~20,000 human genes in 32 normal
tissues derived from massively parallel signature sequen-
cing [47]. The raw data set documents the abundance
values of each short sequence signature tag (with a total of
182,727 tags) in 32 tissues. We mapped these tags to the
regions of the human genome (hg18) that encode genes, in
both orientations. We obtained 105,512 hits in the gene
regions in both orientations and, among them, 68,855 hits
in the gene orientation (p-value< 10−2,000), indicating that
the tags were able to distinguish the transcribed orientation
from the non-transcribed orientation in the genome.
Assigning the tags that hit a gene region and orientation to
the corresponding gene, we obtained a set of tags for each
gene, resulting in a total of 14,516 genes having non-empty
tag sets. We summed up the abundance tissue profiles of
the tags of a gene to create its raw expression profile.
Furthermore, we computed the statistical significance
of a gene being preferentially expressed in a tissue
(termed “tissue specificity”) using an approach similar to
that of Yu et al. [52], which identified tissue-specific
genes from the NCBI Expressed Sequence Tag database.
Let ek(g) be the expression level of gene g in tissue k. The
total expression of gene g in all 32 tissues is,
E gð Þ ¼ ∑
k
ek gð Þ ð7Þ




ek gð Þ ð8Þ
If we randomly throw E(g) darts into 32 areas of sizes
Ek, k= 1, 2, . . .32, and each dart has a probability,
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of hitting area k, we would expect to see E(g) qk darts in
this area with variance E(g)qk(1-qk). Similarly, if gene g
were equally expressed across all tissues, the expected
expression level in tissue i would be E(g)qk with variance
E(g)qk(1-qk). Thus, we used the corresponding Z-score,
Zk gð Þ ¼ ek gð Þ−E gð Þqkﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
E gð Þqk 1−qkð Þ
p ð10Þ
as the tissue specificity of gene g in tissue k. Accordingly,




Zm gð ÞZm hð Þ ð11Þ
We chose the top 1% of these scored gene pairs as the
reference set of co-expressed gene pairs to evaluate the PPI
scoring approaches. There were 1,053,529 co-expression
pairs in this set.
Additional files
Additional file 1: Aggregated human physical PPI data. This tab-
delimited text file contains the aggregated PPI data based on
publications collected from nine databases: BIND, BioGRID, DIP, HPRD,
IntAct, MINT, MIPS, PDZBase, and Reactome.
Additional file 2: Direct interactions supported by known complexes in
PDB. This tab-delimited file contains the protein pairs that have direct
contact in at least one protein complex in PDB.
Additional file 3: IDBOS Ranked PPI data. This tab-delimited file contains
the aggregated PPI data set with the corresponding IDBOS ranking.
Additional file 4: Occurrence Ranked PPI data. This tab-delimited file
contains the aggregated PPI data set with the corresponding occurrence
ranking.
Additional file 5: Hypergeometric Ranked PPI data. This tab-delimited
file contains the aggregated PPI data set with the corresponding
hypergeometric ranking.
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